Clinical TrialAug 4, 2026, 09:20 AM
Silexion SIL204 Preclinical Data Shows Immune-Sensitizing Effects
AI Summary
Silexion Therapeutics announced new positive preclinical data for SIL204, demonstrating its ability to upregulate FAS and downregulate HLA-G in human KRAS-mutant pancreatic and non-small cell lung cancer cell lines. These findings, combined with previously reported MHC-I upregulation, support a coordinated immune-sensitization effect, reinforcing the rationale for combining SIL204 with anti-PD-(L)1 checkpoint inhibitors. The company is advancing SIL204 into Phase 2/3 clinical evaluation, with the first clinical trial site initiated in July 2026.
Key Highlights
- SIL204 treatment significantly upregulated FAS (CD95), an immune “death receptor,” in KRAS-mutant pancreatic and NSCLC cells.
- SIL204 treatment significantly downregulated HLA-G, an immune checkpoint, in KRAS-mutant pancreatic and NSCLC cells.
- Findings support a coordinated immune-sensitization signature across three key immune pathways, including previously reported MHC-I upregulation.
- Immune-modulatory effects observed across four distinct KRAS mutations (G12D, G12V, G12C, G12R) in pancreatic and NSCLC models.
- Data reinforces the scientific rationale for combining SIL204 with anti-PD-(L)1 immune checkpoint inhibitor therapies.
- Silexion is advancing SIL204 into Phase 2/3 clinical evaluation, with the first site initiated in July 2026.
Price Impact
More from SLXN